Plain-English translation of NCT06430684 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing whether empagliflozin, a medication that helps the kidneys manage blood sugar and fluid, can slow the progression of chronic kidney disease in young people. Researchers want to know if it's feasible to recruit and follow 40 youth for this study, and whether the medication improves kidney and heart health markers over 3 months.
Currently, there aren't many proven treatment options specifically for young people whose kidneys are progressively failing. This medication has shown promise in adults with kidney disease, so researchers want to see if it's safe and helpful for children and teenagers—and whether it's practical to study it in this age group.
You likely qualify if…
You likely don't qualify if…
If you enroll, you'll be randomly assigned to either start the medication or continue your regular kidney care for 3 months. If you receive the medication, you'll take a pill once daily and visit the clinic at 4 and 8 weeks for check-ups and blood or urine tests. All participants have clinic visits at the beginning and end of the study, plus phone check-ins with the research team every 2 weeks to see how you're doing.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States